@article {Borena2021.02.19.21252089, author = {Wegene Borena and Zolt{\'a}n B{\'a}nki and Katie Bates and Hannes Winner and Lydia Riepler and Annika R{\"o}ssler and Lisa Pipperger and Igor Theurl and Barbara Falkensammer and Hanno Ulmer and Andreas Walser and Daniel Pichler and Matthias Baumgartner and Sebastian Sch{\"o}nherr and Lukas Forer and Ludwig Knabl and Reinhard W{\"u}rzner and Dorothee von Laer and J{\"o}rg Paetzold and Janine Kimpel}, title = {Follow-up study in the ski-resort Ischgl: Antibody and T cell responses to SARS-CoV-2 persisted for up to 8 months after infection and transmission of virus was low even during the second infection wave in Austria}, elocation-id = {2021.02.19.21252089}, year = {2021}, doi = {10.1101/2021.02.19.21252089}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Background In early March 2020, a SARS-CoV-2 outbreak in the ski resort Ischgl in Austria initiated the spread of SARS-CoV-2 throughout Austria and Northern Europe. In a cross-sectional study, we found that the seroprevalence in the adult population of Ischgl had reached 45\% by the end of April. To answer the question of how long immunity persists and what effect this high-level immunity had on virus transmission, we performed a follow-up study in early November, 2020.Methods Of the 1259 adults that participated in the baseline study, 801 could be included in the follow-up. The study involved the analysis of binding and neutralizing antibodies and T cell responses. In addition, the incidence of SARS-CoV-2 infections in Ischgl was compared to the incidence in similar municipalities in Tyrol throughout 2020.Findings For the 801 individuals that participated in both studies, the seroprevalence declined from 51.4\% (95\% confidence interval (CI) 47.9 - 54.9) to 45.4\% (95\% CI 42.0 - 49.0). Median antibody concentrations dropped considerably but antibody avidity increased. T cell responses were analysed in 93 cases, including all 4 formerly seropositive cases that had lost antibodies in all assays, three of which still had detectable T cell memory. In addition, the incidence in the second COVID-19 wave that hit Austria in November 2020, was significantly lower in Ischgl than in comparable municipalities in Tyrol or the rest of Austria.Interpretation This study has important implications as it shows that although antibodies to SARS-CoV-2 declined, T and B cell memory can be detected for up to 8 months. Complemented by infection prevention measures a level of around 40-45\% immunity in Ischgl significantly reduced local virus transmission during the second wave in Austria in November 2020.Funding Funding was provided by the government of Tyrol and the FWF Austrian Science Fund.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study has been supported by the state of Tyrol. KB has been supported by a FWF Austrian Science Fund Lise Meitner Award [M-3069-B].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical committee of the Medical University of InnsbruckAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUpon publication of our study, the data and codes will be available from the corresponding authors upon receipt of a suitable request.}, URL = {https://www.medrxiv.org/content/early/2021/02/23/2021.02.19.21252089}, eprint = {https://www.medrxiv.org/content/early/2021/02/23/2021.02.19.21252089.full.pdf}, journal = {medRxiv} }